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Abstract
Background and Aims—Many US adults use calcium supplements to address inadequate 
dietary intake and improve bone health. However, recent reports have suggested that use of 
calcium supplements may elevate cardiovascular disease (CVD) risk. In this study, we examined 
associations between baseline calcium supplement use and incident myocardial infarction (MI) 
(n=208 events) and CVD events (n=641 events) over 10.3 years in men and women from the 
Multi-Ethnic Study of Atherosclerosis (MESA) cohort (n=6,236), with dietary calcium intake at 
baseline also examined as a supplementary objective.
Methods and Results—Using Cox proportional hazards models, no compelling associations 
between calcium intake from supplements or diet and incident CVD events were observed upon 
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multivariate adjustment for potential confounders. An association with lower MI risk was observed 
comparing those with low levels of calcium supplement use (1-499 mg) to those using no calcium 
supplements (hazard ratio 0.69, 95% CI 0.48, 0.98, p=0.039). Relationships were homogeneous by 
gender, race/ethnicity, or chronic kidney disease. Results were also similar when the analysis was 
limited to postmenopausal women only.
Conclusion—Analysis of incident MI and CVD events in the MESA cohort does not support a 
substantial association of calcium supplement use with negative cardiovascular outcomes.
Keywords
calcium; supplements; myocardial infarction; cardiovascular disease; Multi-Ethnic Study of 
Atherosclerosis
Introduction
Calcium is essential for bone health, but most US adults have calcium intakes considered 
inadequate by Institute of Medicine recommendations [1-3]. To address this, large portions 
of the population use calcium supplements, with >50% of men and >60% of women over 60 
years old reporting calcium supplement use in the 2003-2006 National Health and Nutrition 
Examination survey [1,3]. Calcium supplementation has been linked to increases in bone 
mineral density [4] and reduced risk of fractures [5], though evidence is mixed [6].
Concern that calcium supplementation may increase cardiovascular disease (CVD) risk was 
originally raised by the Auckland calcium clinical trial, which included 1,471 healthy 
postmenopausal women. In this trial, there was a significant increase in adjudicated self-
reported myocardial infarction (MI) (relative risk (RR) 2.12, 95% confidence interval (CI) 
1.01 to 4.47, p=0.047) in women randomized to calcium supplementation (1000 mg/day) 
[7]. Comparing calcium supplementation to placebo, a similar increase in MI risk was also 
observed in a subsequent meta-analysis of five randomized trials with patient level data and 
eleven additional randomized trials with trial level data [8]. The results of the large Women's 
Health Initiative (WHI) calcium-vitamin D trial have been disputed. A modest elevation in 
MI risk was observed by Bolland et al. in participants not taking personal calcium 
supplements at baseline (hazard ratio (HR) 1.22, 95% CI 1.00 to 1.50, p=0.05, n=16,718) 
[9], but the WHI clinical trial investigators reported no adverse effect of calcium and vitamin 
D on any cardiovascular end point (HR 1.04; 95% CI, 0.92 to 1.18, p=0.50, n=36,282) 
[10,11], with no adverse effect observed when analyses included only those with no personal 
calcium supplement use at baseline [11]. A recent meta-analysis of both published and 
unpublished randomized trials using verified events also found no associations of calcium 
supplements with coronary heart disease (CHD) events (n=48,460) or all-cause mortality 
(n=62,383) [12]. Results of observational cohort studies have also been mixed [13,11,14,15]. 
Based on this conflicting literature on the CVD impacts of calcium supplementation, we 
examined the association of calcium supplementation and incident cardiovascular events in 
the Multi-Ethnic Study of Atherosclerosis (MESA).
The MESA cohort presents a unique opportunity to examine this question in a race/ethnic 
diverse population with well-documented and adjudicated measures of MI and other CVD 
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events, measures of cardiovascular risk factors, and food questionnaires. Most previous 
studies examining associations of calcium supplementation with negative CVD outcomes 
have focused on predominantly European populations. Moreover, associations of calcium 
supplementation and CVD risk have been largely studied in postmenopausal women, while 
MESA provides an opportunity to assess the association of calcium and CVD events in 
younger women and men.
Methods
Study Population
MESA is a community-based cohort study designed to determine the prevalence, 
determinants, and progression of subclinical CVD which recruited men and women aged 
45-84 from four major race/ethnicity groups from 6 different locations in the United States 
(2000-2002). All participants were free of clinical CVD at baseline [16]. All subjects with 
calcium supplementation data (n=6,236) were included in our analyses. This included 
participants from all 6 recruitment sites, including Wake Forest University (15.6%), 
Columbia University (14.6%), Johns Hopkins University (15.3%), University of Minnesota 
(16.1%), Northwestern University (17.9%), and University of California, Los Angeles 
(20.4%); calcium supplement use category was associated with recruitment site (p<0.0001), 
and site was included as a covariate in all adjusted models. Data for clinical and 
demographic factors included in this study were collected in Exam 1, with a standard 
questionnaire used to determine participant's basic demographic data, smoking status, 
medication use, and medical history. Physical activity was assessed using a semiquantitative 
questionnaire, and usual diet was assessed using a previously validated food frequency 
questionnaire (FFQ) [16]. The FFQ is a modified version of the Block FFQ, which was 
based on the FFQ used in the Insulin Resistance Atherosclerosis Study and modified to 
account for race/ethnic differences in usual diet [17,18]. The FFQ was used to determine if 
participants used calcium supplements once a week or more and, if so, the number of pills 
consumed per week and dose of calcium in each pill.
Data on total dietary energy intake (kcal) and total dietary calcium intake (mg) was also 
drawn from this FFQ. For approximately 1/3 of the participants in MESA, data were 
unavailable on the intake of 14 foods (fruit juice, dark / whole grains, fruit, salty snacks, 
other vegetables, leafy green vegetables, yoghurt, potato, red meat, high-fat & processed 
meat, high-fat dairy, desserts, cottage cheese and legumes). As the majority of these 
participants were from one of two MESA field centers, these data may not be missing at 
random. For these 14 intakes for this portion of the MESA population, imputation was 
conducted using sequential chained regression [19] implemented in Stata 12, accounting for 
basic demographic factors.
Basic clinical measures, including blood pressure, lipid levels, and estimated glomerular 
filtration rate using the CKD-EPI equation [20], were also assessed at the baseline exam 
[16]. The blood pressure measures were the average of the first two of three seated readings 
using the Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, 
Tampa, Florida) [16]. Diabetes was defined as serum glucose levels of ≥126 mg/dL or use of 
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medications. Chronic kidney disease (CKD) was defined as an estimated glomerular 
filtration rate < 60 ml/min/1.73 m2.
Average follow-up time was 10.3 (standard deviation 2.7) years. A standard protocol was 
used by MESA to adjudicate events, as has been previously described [16]. Briefly, 
participants were contacted every 9-12 months by telephone interview and asked about 
interim hospital admissions, CVD related outpatient diagnoses and procedures, and deaths. 
These reports were confirmed using death certificates and medical records. Two physicians 
adjudicate each endpoint, with the full committee adjudicating in case of disagreement. In 
some studies, calcium supplement use significantly increased MI risk but not risk of stroke 
and other CVD outcomes [7,8], so MI events were the main focus for our analyses. 
However, we also considered all CVD events, defined as MI, resuscitated cardiac arrest, 
definite angina, probable angina that was followed by revascularization, stroke, and stroke, 
CHD, atherosclerotic, or other CVD death. In total, there were 208 incident myocardial 
infarctions and 641 CVD events; these 641 events included 169 CVD related deaths, 183 
strokes, 26 resuscitated cardiac arrests, and 187 cases of definite angina, with a number of 
individuals having multiple CVD events.
Statistical Analysis
Associations of calcium supplementation categories, as well as dietary calcium quartiles, 
with incident MI and CVD events were analyzed using Cox proportional hazards models. 
Daily supplemental calcium intake was divided into four categories: no calcium 
supplements, 1-499 mg, 500-999 mg, and ≥1000 mg. Dietary calcium, which included 
calcium from food intake only, not supplements, was adjusted for total energy intake using a 
residual method before dietary calcium intake quartiles were derived [21], with the cohort 
then divided into 4 equal quartiles based on total energy intake-adjusted dietary calcium 
measures. Results are shown both for our main analysis of all men and women in MESA 
with calcium supplementation data and an exploratory analysis in postmenopausal women 
only, the group in which the negative CVD impacts of calcium supplementation were 
initially reported [7]. We also analyzed use of any calcium supplements as a dichotomous 
variable. We analyzed each supplement use category as compared to no supplement use, any 
supplement use as compared to no supplement use, and a test for trend across supplement 
use categories, in order to increase our ability to detect an association of incident events with 
calcium supplement use whether or not this relationship was dependent on supplementation 
dose. Total energy intake-adjusted dietary calcium quartiles were also analyzed with respect 
to the lowest quartile and with a test for trend across quartiles.
Analyses were adjusted for potential confounders including age, gender, race/ethnicity, 
recruitment site, education, income, HDL, lipid-lowering medication use, systolic blood 
pressure, diastolic blood pressure, diabetes status, body mass index, estimated glomerular 
filtration rate, physical activity (moderate and vigorous physical activity total, met-min/wk 
msu), cigarette use (never, former, or current), calcium supplementation category, and total 
energy intake-adjusted dietary calcium quartile. We considered but did not adjust for total 
cholesterol and hypertension medication use, as there was no significant trend for these 
variables across calcium supplement categories. In sensitivity analyses, additional 
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adjustment for these variables did not substantively change results, nor did additional 
adjustment for total energy intake in Model 3. Higher calcium supplementation category was 
also associated with higher seated pulse pressure; adjusting for pulse pressure instead of 
systolic and diastolic blood pressure in Model 3 also did not substantively change the 
results. Multiplicative interactions between gender, race/ethnicity, and CKD and calcium 
supplementation categories and energy-adjusted calcium intake quartiles were also assessed. 
Additive interaction, as measured by relative risk due to interaction (RERI), was also 
assessed using the method developed by Li and Chambless [22]. For determining trends in 
clinical and demographic variables across calcium supplementation categories, linear 
regression models for continuous measures and logistic regression models for binary 
measures were used, with differences in discrete variables such as smoking status, income, 
and education assessed using multinomial logistic regression, with the likelihood ratio test p-
value used to assess significance. All analyses were implemented in SAS 9.3, and p-values < 
0.05 were considered statistically significant for all analyses, including interaction terms.
Results
Clinical and demographic characteristics of participants stratified by supplemental calcium 
intake categories are displayed in Table 1. Individuals using high levels of calcium 
supplements had lower diabetes prevalence, less current smoking, higher HDL cholesterol, 
and lower BMI, emphasizing the importance of adjusting for these risk factors. By contrast, 
individuals not taking supplements performed more moderate and vigorous physical activity, 
had higher estimated glomerular filtration rate, and had lower prevalence of chronic kidney 
disease. Individuals taking calcium supplements were more likely to be white and female 
and have higher levels of educational attainment and income.
We found no evidence that calcium supplement use was associated with elevated risk of MI 
or CVD events (Table 2). Individuals using a low dose of calcium supplements (1-499 mg) 
had a lower risk of MI than individuals taking no calcium supplements (HR 0.69, 95% CI 
0.48, 0.98, p=0.039 in Model 3). A trend towards lower MI risk with increasing calcium 
supplement use was also observed in unadjusted Model 1 (HR 0.84, 95% CI 0.73, 0.97, 
p=0.020), but this was attenuated upon adjustment for further confounders (Model 3), 
including education, income, HDL, lipid-lowering medication use, systolic blood pressure, 
diastolic blood pressure, diabetes status, body mass index, estimated glomerular filtration 
rate, physical activity, cigarette use, and energy-adjusted dietary calcium quartile. Similar 
results were observed for calcium supplement use as a dichotomous variable, with an 
association with lower MI risk in unadjusted models (HR 0.68, 95% CI 0.51, 0.90, p=0.007) 
attenuated upon confounder adjustment in Model 3. No significant multiplicative or additive 
interactions between gender, race/ethnicity, or CKD and calcium supplementation categories 
were observed (p≥0.34) for either MI or all CVD events.
No statistical significant p-values were seen for any of the models assessing the association 
of energy-adjusted dietary calcium intake quartiles with MI and CVD events (Table 3) or for 
multiplicative or additive interactions with gender, race/ethnicity, or CKD (p≥0.12). Dietary 
intake of calcium was adjusted for total energy intake using a residual method before 
quartiles were derived.
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In analyses limited to postmenopausal women only, results were similar. No associations of 
calcium supplement use categories and energy-adjusted dietary calcium intake quartiles with 
MI or all CVD events were observed (Tables 4 and 5).
Discussion
In a large multi-ethnic population of 6,236 individuals from the MESA cohort free of 
clinical CVD at baseline, no associations of calcium supplement use with risk of incident 
CVD events were observed. Additionally, no association was observed between dietary 
calcium intake and incident CVD events. When analyses were restricted to postmenopausal 
women, the group in which potential negative impacts of calcium supplementation were first 
reported [7], the results were similar. As supplementary analyses (results not shown), we 
also analyzed associations of quartiles of the sum of calcium intake from supplements and 
total energy intake-adjusted dietary calcium. No significant associations were observed, 
either in the entire cohort or postmenopausal women only, for fully adjusted models. To 
increase the sample size for the calcium supplement use group, we also performed an 
analysis where all individuals using ≥500 mg calcium supplements were analyzed as a single 
category; no associations with increased risk of incident CVD were observed. These findings 
suggest that calcium intake has either no impact or a small effect on CVD event risk in this 
diverse cohort.
A number of other analyses of both randomized clinical trials and observational studies have 
also found no association between calcium supplementation and CVD outcomes, similar to 
the results observed in our study. A number of large observational cohort studies have found 
no association of calcium supplementation with CVD risk [14,11,15]. The investigators for 
the large WHI calcium-vitamin D trial found no negative CVD impact of calcium 
supplementation [11,10], and a recent meta-analysis of this and other clinical trials found no 
association of calcium supplementation with or without vitamin D on CHD or all-cause 
mortality [12]. Many of the original reports of calcium supplementation increasing risk of 
CVD events were in the setting of randomized, placebo controlled clinical trials [8,7]. While 
these controlled trials clearly have some advantages over observational trials such as MESA, 
the follow-up period for most trials is also generally short, with relatively few events. For 
our analysis in MESA, we had, on average, over 10 years of follow-up, with 208 MI events 
and 641 CVD events. We found no evidence favoring an association of calcium 
supplementation with elevation in MI or CVD events; however, we cannot exclude a small 
elevation in risk with use of calcium supplements, with a 95% CI for use of any calcium 
supplementation of 0.56 to 1.02 for MI and 0.80 to 1.12 for all CVD in fully adjusted 
models. Another limitation of this analysis is that data was not available for use of vitamin D 
or vitamin K supplements; intake of both vitamins may impact calcium absorption [23,24]. 
However, through an ancillary study, data was available for annualized serum concentration 
of 25-hydroxyvitamin D (25(OH)D), adjusted for seasonal variation in measurement; higher 
levels of calcium supplement use was associated with higher serum vitamin D (p<0.0001), 
likely in part due to concurrent use of calcium and vitamin D supplements in some 
participants. However, results of fully adjusted models were similar with or without 
adjustment for serum vitamin D (Supplementary Tables 1 and 2).
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Our negative results are consistent with the lack of a clear mechanism for why calcium 
supplementation would increase CVD risk. Vascular calcification, a measure of subclinical 
CVD risk, has been suggested as a potential mediator of the negative CVD impacts of 
calcium supplementation [25,9]. However, studies have consistently found no association 
between calcium supplement use and vascular calcification [26-28]. Other problems with 
reports of elevated CVD risk with calcium supplementation, including lack of adjustment for 
baseline CVD risk factors, no correction for multiple endpoints testing, and trials not 
specifically designed for assessing CVD risk, have been reviewed previously [29].
Our supplemental analysis of dietary calcium intake in MESA also found no associations of 
dietary calcium and CVD risk. In general, studies have found increased dietary calcium 
intake to be inversely related to CVD events, but results are mixed [30,31]. A recent meta-
analysis of observational cohort studies reported a U-shaped association between dietary 
intake of calcium and CVD mortality, with lower mortality risk for individuals with intakes 
around 800 mg/day and higher risk with lower or higher intakes [14]. However, we observed 
no significant inverse relationships with CVD risk for individuals in quartile 3, who had 
calcium intakes around 800 mg/day level (642.0 - 876.3 mg). Similar to our results, a 
number of studies have found no link between dietary calcium intake and CVD [30-32].
In summary, our results do not support the hypothesis that use of calcium supplements or 
differences in dietary calcium intake increase risk of MI or all CVD events. Results were 
similar in postmenopausal women.
Supplementary Material
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RR relative risk
RERI relative risk due to interaction
WHI Women's Health Initiative
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Highlights
Associations of calcium supplement use and cardiovascular disease (CVD) events were 
examined.
The study included men and women from the Multi-Ethnic Study of Atherosclerosis.
Calcium supplements were not associated with elevated CVD risk.
Dietary calcium intake was also not associated with incident CVD events.
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Table 1
Demographic and clinical characteristics of the MESA cohort at Exam 1 (2000-2002), stratified by calcium 
supplement intake categories. The reported p-value is for the trend across calcium supplement categories using 
linear regression for continuous variables and logistic regression for dichotomous variables. For discrete 
variables such as smoking status and site, the likelihood ratio test p-value from multinomial logistic regression 
is reported.
Mean (Standard Deviation) or %
Calcium 
Supplement 
Category 1 (0 
mg, n=3370)
Calcium 
Supplement 
Category 2 
(1-499 mg, 
n=1550)
Calcium 
Supplement 
Category 3 
(500-999 mg, 
n=620)
Calcium 
Supplement 
Category 4 
(≥1000 mg, 
n=696)
p-value
Age (years) 62 (10) 63 (10) 63 (10) 64 (10) <0.0001
Male Gender (%) 55 51 25 20 <0.0001
Body Mass Index (kg/m2) 29 (5.4) 28 (5.2) 27 (5.6) 27 (5.2) <0.0001
HDL Cholesterol (mg/dL) 49 (14) 51 (14) 55 (16) 58 (17) <0.0001
Total Cholesterol (mg/dL) 194 (36) 194 (35) 194 (34) 196 (34) 0.151
Lipid-lowering Medication Use (%) 15 18 18 17 0.045
Systolic Blood Pressure (mmHg) 127 (22) 126 (21) 125 (22) 126 (22) 0.042
Diastolic Blood Pressure (mmHg) 73 (10) 72 (10) 69 (10) 69 (10) <0.0001
Hypertension Medication Use (%) 37 39 34 37 0.991
Estimated Glomerular Filtration Rate (CKD-
EPI Equation) (ml/min/1.73 m2)
79 (17) 77 (16) 78 (16) 75 (15) <0.0001
Chronic Kidney Disease (%) 12 13 14 16 0.006
Moderate and Vigorous Physical Activity 
Total (met-min/wk m-su)
5821 (6187) 5806 (5703) 5370 (4999) 5248 (5441) 0.009
Diabetes Status (%) 14 12 8.4 7.6 <0.0001
Former Cigarette Smoking (%) 36 39 32 37 <0.0001
Current Cigarette Smoking (%) 15 12 7.1 6.1
Race/Ethnicity: White, Caucasian (%) 33 45 42 56 <0.0001
Race/Ethnicity: Chinese American (%) 12 13 19 12
Race/Ethnicity: Black, African-American 
(%)
29 25 20 18
Race/Ethnicity: Hispanic (%) 26 17 20 14
Education Category 1 to 3: Less than High 
School (%)
23 12 16 9.8 <0.0001
Education Category 4: Completed High 
School/GED (%)
18 16 19 22
Education Category 5 to 7: Some College, 
Technical School Certificate, or Associate 
Degree (%)
28 28 28 28
Education Category 8 to 9: Bachelor's Degree 
or Greater (%)
32 43 37 40
Income Category 1 to 5: <$20,000 (%) 26 22 20 18 <0.0001
Income Category 6 to 9: $20,000-39,999 (%) 27 24 31 27
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Mean (Standard Deviation) or %
Calcium 
Supplement 
Category 1 (0 
mg, n=3370)
Calcium 
Supplement 
Category 2 
(1-499 mg, 
n=1550)
Calcium 
Supplement 
Category 3 
(500-999 mg, 
n=620)
Calcium 
Supplement 
Category 4 
(≥1000 mg, 
n=696)
p-value
Income Category 10 to 13: ≥$40,000 (%) 47 55 49 55
Annualized Serum Concentration of 25-
Hydroxyvitamin D (25(OH)D) (ng/mL)
23 (10) 29 (11) 30 (9.1) 33 (11) <0.0001
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